Lake Street analyst Brooks O’Neil initiated coverage of LifeVantage (LFVN) with a Buy rating and $26 price target The company’s products activate physical wellness by using science-based formulas that unlock genes to restore optimal cellular function, says the analyst, who expects rapid growth of the MindBody GLP-1 System that targets a demographic looking for a natural approach to the weight loss benefits of GLP-1s to drive the company’s results this quarter and going forward. While “only” modeling 2% revenue growth in FY25, the firm expects EPS growth of 196% and think shares are “attractively valued,” the analyst tells investors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio